Business Wire

Mopria Print Service 2.3 Unleashes New Mobile Printing Capabilities with Share-to-Print from Android Devices

Del

The Mopria® Alliance, a global non-profit membership organization chartered to drive industry-wide standards for mobile printing, today released Mopria Print Service 2.3, expanding mobile printing support by allowing users to print using the Share feature from many of their favorite apps. The Mopria Print Service 2.3 is also compatible with Android 8.0 Oreo™ whose default printing solution utilizes core Mopria technology allowing printing to more than 100 million Mopria certified printers. The update is available on the Google Play™ Store for all Android devices.

The Mopria Print Service 2.3 utilizes the Share feature already available in many popular apps including Facebook, Flipboard, LinkedIn, Twitter and Pinterest, giving users the power to print easily. When using the Share feature, users will see a Mopria Print Service option is included as an option after email and messaging. The Share icon is conspicuously placed and users simply select the Mopria Print Service option, select their printer, adjust settings and print.

The new release also supports finishing options such as punching, folding and stapling in many orientations as well as a new interface, adding the ability for users to quickly see available printers and determine their status. This provides a convenient starting point for adding or hiding printers, accessing Mopria settings, troubleshooting printing issues and viewing Mopria certified printer lists. The new interface includes tutorials that guide new users through the mobile printing process and provides tips, adding one of the most user-requested features to the service.

“We continue to add functionality to the Mopria Print Service making mobile printing from Android devices as easy an experience as possible,” said Brent Richtsmeier, Chairperson of the Mopria Alliance Steering Committee. “With expanded options to print using the Share feature on the most beloved apps in the world, users are rediscovering the convenience of mobile printing.”

Since its launch, the Mopria Print Service has enabled printing on Android smartphones and tablets to Mopria certified printers. It lets users easily customize color, number of copies, duplex, paper size, page range, media type and orientation, as well as workplace features like user authentication, pin printing and accounting capabilities all without having to install printer brand specific apps.

In the four years since the establishment of the Mopria Alliance by founders Canon, HP, Samsung and Xerox, the nonprofit membership organization has grown to 21 members representing the worldwide printer business. In addition to the founding companies, the Mopria Alliance today includes Adobe, Konica Minolta, Qualcomm, Lexmark, Kyocera, Toshiba, Brother, Epson, Fuji Xerox, Microsoft, NEC, Pantum, Ricoh, YSoft, Sharp, Dell and Primax.

Mopria technology currently has more than 700 million installs and is expected to exceed 1 billion in less than one year. While the Mopria Alliance will continue its efforts to make mobile printing easy, it will also expand its focus to standardizing cloud printing and scanning. Its goal is to make these solutions more accessible and intuitive for both consumer and business users. For the latest list of Mopria certified printers and print accessories, please visit http://mopria.org/certified-products.

About the Mopria ® Alliance

The Mopria® Alliance is a non-profit membership organization of leading global technology companies with the initial goal of simplifying printing from smartphones, tablets and other devices. The Alliance develops and promotes technology standards that deliver an intuitive experience connecting different devices and mobile operating systems. The adoption of these standards allow users to seamlessly interact with a printer, regardless of brand. Plus, app downloads and setups for new mobile devices or printers will become unnecessary. Look for Mopria certified printers and accessories for easy printing with Mopria-enabled mobile devices. Learn more at www.mopria.org or download the latest Mopria software on the Google Play Store.

Contact information

Tech Image
Harvey Henao
(312) 673-6059
harvey.henao@techimage.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45Pressemelding

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10Pressemelding

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an